PPARA and metabolic syndrome: Modern research has found that PPAR agonists have important metabolic regulatory effects and PPAR agonists, such as thiazolidinediones, fibrates, and gliclazides, are now approved as clinical agents for the treatment of dyslipidemia and DM (Iglesias and Díez, 2006).